Your browser doesn't support javascript.
loading
A Retrospective Database Analysis of Neonatal Morbidities to Evaluate a Composite Endpoint for Use in Preterm Labor Clinical Trials.
Pimenta, Jeanne M; Ebeling, Myla; Montague, Timothy H; Beach, Kathleen J; Abell, Jill; O'Shea, Michael T; Powell, Marcy; Hulsey, Thomas C.
Afiliação
  • Pimenta JM; Real World Evidence (Epidemiology), GSK, Uxbridge, Middlesex, United Kingdom.
  • Ebeling M; Division of Neonatology, Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina.
  • Montague TH; Clinical Statistics, GSK, Philadelphia, Pennsylvania.
  • Beach KJ; Maternal Neonatal Health Unit, GSK, Research Triangle Park, North Carolina.
  • Abell J; Clinical Effectiveness and Safety Clinical Evaluation Science, GSK, Philadelphia, Pennsylvania.
  • O'Shea MT; Janssen Scientific Affairs, Real World Evidence, Philadelphia, Pennsylvania.
  • Powell M; Department of Pediatrics (Neonatology Section), University of North Carolina, Chapel Hill, North Carolina.
  • Hulsey TC; Safety Evaluation and Risk Mitigation, GSK, Research Triangle Park, North Carolina.
AJP Rep ; 8(1): e25-e32, 2018 Jan.
Article em En | MEDLINE | ID: mdl-29527406
ABSTRACT
Objective To propose and assess a composite endpoint (CE) of neonatal benefit based on neonatal mortality and morbidities by gestational age (GA) for use in preterm labor clinical trials. Study Design A descriptive, retrospective analysis of the Medical University of South Carolina Perinatal Information System database was conducted. Neonatal morbidities were assessed for inclusion in the CE based on clinical significance/risk of childhood neurodevelopmental impairment, frequency, and association with GA in a mother-neonate linked cohort, comprising women with uncomplicated singleton pregnancies delivered at ≥24 weeks' GA. Results Among 17,912 mother-neonate pairs, neonates were at a risk of numerous severe but infrequent morbidities. Clinically important, predominantly rare events were combined into a CE comprising neonatal mortality and morbidities, which decreased in frequency with increasing GA. The highest CE frequency occurred at <31 weeks. High frequency of respiratory distress syndrome, bronchopulmonary dysplasia, and sepsis drove the CE. Median length of hospital stay was longer at all GAs in those with the CE compared with those without. Conclusions Descriptive epidemiological assessment and clinical input were used to develop a CE to measure neonatal benefit, comprising clinically meaningful outcomes. These empirical data and CE allowed trials investigating tocolytics to be sized appropriately.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: AJP Rep Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: AJP Rep Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido